Related Experiment Video

Updated: Jan 4, 2026

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

3.2K

Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?

Ellen Sidransky1, David Arkadir2,3, Peter Bauer4

  • 1Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|November 12, 2019
PubMed
Abstract

No abstract available in PubMed .

Keywords:
GBA1-associated parkinsonismGaucher carriersParkinson's diseaseglucocerebrosidasesubstrate reduction therapy

More Related Videos

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

32.3K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.1K

Related Experiment Videos

Last Updated: Jan 4, 2026

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease
04:08

Applying the RatWalker System for Gait Analysis in a Genetic Rat Model of Parkinson's Disease

Published on: January 18, 2021

3.2K
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

32.3K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.1K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

905
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
905
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.6K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.6K

Articles linked to this work by shared authors, journal, and citation graph.

Sex-Specific Association of Rasagiline with Motor Progression in GBA1-Associated Parkinson's Disease.

Life (Basel, Switzerland)·2026

Glucosylsphingosine (Lyso-Gb1) Dynamics in Untreated States in Gaucher Disease.

International journal of molecular sciences·2026

Improvement of Bone Mineral Density in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: Results from Clinical Studies.

Journal of clinical medicine·2026

The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2025

Bidirectional regulation of glycoprotein nonmetastatic melanoma protein B by β-glucocerebrosidase deficiency in GBA1 isogenic dopaminergic neurons from a patient with Gaucher disease and parkinsonism.

bioRxiv : the preprint server for biology·2025

Prodromal Parkinsonian Features in Carriers of Gaucher Disease Compared to Controls.

Life (Basel, Switzerland)·2025

Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Fifteen-Year Outcomes of Bilateral Pallidal Stimulation in Isolated Generalized Dystonia: Characterization of Therapeutic Response and Emergence of Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2026

Dopamine-Deficiency-Related Reorganization of the Somatomotor Network in Prodromal and Early Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

The Effect of LRRK2 and GBA1 Mutations on Survival in Early- and Late-Onset Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Gender Disparity in Movement Disorders Research Authorship: Progress and Persistent Gaps Across a Decade.

Movement disorders : official journal of the Movement Disorder Society·2026

Parkinson's Disease and Retinal Age Gap: A Cross-Sectional Analysis.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us